WO2013061105A3 - Glycogen phosphorylase inhibitors - Google Patents

Glycogen phosphorylase inhibitors Download PDF

Info

Publication number
WO2013061105A3
WO2013061105A3 PCT/HU2012/000116 HU2012000116W WO2013061105A3 WO 2013061105 A3 WO2013061105 A3 WO 2013061105A3 HU 2012000116 W HU2012000116 W HU 2012000116W WO 2013061105 A3 WO2013061105 A3 WO 2013061105A3
Authority
WO
WIPO (PCT)
Prior art keywords
hydrogen
glycogen phosphorylase
phosphorylase inhibitors
compounds
formula
Prior art date
Application number
PCT/HU2012/000116
Other languages
French (fr)
Other versions
WO2013061105A2 (en
WO2013061105A8 (en
Inventor
László SOMSÁK
Éva BOKOR
Marietta VÁGVÖLGYINÉ TÓTH
László JUHÁSZ
Katalin CZIFRÁK
Bálint KÓNYA
Sándor KUN
András PÁHI
Béla SZŐCS
Gergely VARGA
Gergely Pál
Tibor DOCSA
Lászlóné KÓDER
Károlyné NAGY
Original Assignee
Debreceni Egyetem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Debreceni Egyetem filed Critical Debreceni Egyetem
Publication of WO2013061105A2 publication Critical patent/WO2013061105A2/en
Publication of WO2013061105A3 publication Critical patent/WO2013061105A3/en
Publication of WO2013061105A8 publication Critical patent/WO2013061105A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to compounds of formula (I) and stereoisomers, tautomers and pharmaceutically acceptable salts thereof and processes for preparing them. In formula (I) X is -CH= or -N= or -N(R") -; Y is -N= or -N(R") -; R is an alkyl group, an aryl group or a heteroaryl group, which groups are unsubstituted or substituted; R' is hydrogen or PG1, R" is hydrogen or PG2, R"' is hydrogen or R'OCH2-; n is an integer of 1 to 3. The invention also relates to pharmaceutical compositions containing these compounds. The compounds according to the invention are glycogen phosphorylase inhibitors and can be used e.g. for the treatment of type 2 diabetes, cardiovascular disorders and tumorous growth.˙
PCT/HU2012/000116 2011-10-28 2012-10-27 Glycogen phosphorylase inhibitors WO2013061105A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
HUP1100602 2011-10-28
HUP1100602 2011-10-28
HUP1200475 2012-08-14
HUP1200475 2012-08-14

Publications (3)

Publication Number Publication Date
WO2013061105A2 WO2013061105A2 (en) 2013-05-02
WO2013061105A3 true WO2013061105A3 (en) 2013-07-04
WO2013061105A8 WO2013061105A8 (en) 2013-09-19

Family

ID=89663007

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/HU2012/000116 WO2013061105A2 (en) 2011-10-28 2012-10-27 Glycogen phosphorylase inhibitors

Country Status (1)

Country Link
WO (1) WO2013061105A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112125891B (en) * 2019-06-24 2022-06-07 华东师范大学 N2Selective tetrahydrofuran/tetrahydrothiophene substituted triazole derivative and synthesis method and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050233988A1 (en) * 2003-08-01 2005-10-20 Tanabe Seiyaku Co., Ltd. Novel compounds
WO2011047113A1 (en) * 2009-10-14 2011-04-21 Janssen Pharmaceutica Nv Process for the preparation of compounds useful as inhibitors of sglt2

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050233988A1 (en) * 2003-08-01 2005-10-20 Tanabe Seiyaku Co., Ltd. Novel compounds
WO2011047113A1 (en) * 2009-10-14 2011-04-21 Janssen Pharmaceutica Nv Process for the preparation of compounds useful as inhibitors of sglt2

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BENLTIFA, MAHMOUD ET AL.: "In search of glycogen phosphorylase inhibitors: 5- Substituted 3-c- glucopyranosyl-1,2,4-oxadiazoles from beta-D-glucopyranosyl cyanides upon cyclization of 0-acylamidoxime intermediates", EUROPEAN JOURNAL OF ORGANIC CHEMISTRY, vol. 18, 2006, pages 4242 - 4256 *
DATABASE CA BENLTIFA, MAHMOUD ET AL.: "In search of glycogen phosphorylase inhibitors: 5- Substituted 3-c- glucopyranosyl-1,2,4-oxadiazoles from beta-D-glucopyranosyl cyanides upon cyclization of O-acylamidoxime intermediates", accession no. 46:8163 *
GRANIER, THIERRY ET AL.: "Synthesis and evaluation as glycosidase inhibitors of 1H- imidazol-2-yl C-glycopyranosides", HELVETICA CHIMICA ACTA, vol. 78, no. 7, 1995, pages 1738 - 1746, XP055074587 *

Also Published As

Publication number Publication date
WO2013061105A2 (en) 2013-05-02
WO2013061105A8 (en) 2013-09-19

Similar Documents

Publication Publication Date Title
WO2017123884A8 (en) Heterocyclic compounds as rsv inhibitors
WO2009155121A3 (en) Inhibitors of pi3 kinase
WO2009150137A3 (en) Pyrazine derivatives as epithelial sodium channel blockers
WO2012007877A3 (en) N- sulfonylbenzamides as inhibitors of voltage - gated sodium channels
NZ588830A (en) Inhibitors of protein kinases
GEP20125581B (en) Sulfonyl amide derivatives for treatment of abnormal cell growth
WO2008055870A8 (en) Glucopyranosyl-substituted benzyl-benzonitrile derivatives, medicaments containing such compounds, their use and process for their manufacture
WO2008034859A8 (en) Glucopyranosyl-substituted difluorobenzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
WO2012061418A3 (en) Benzamides and nicotinamides as syk modulators
WO2009122285A8 (en) Oxytocin analogues
TW200745066A (en) Novel PTP1B inhibitors
WO2008003766A3 (en) 4-heter0cycl0alkylpyri(mi)dines, process for the preparation thereof and their use as medicaments
WO2012122340A8 (en) Soluble guanylate cyclase activators
WO2009125434A3 (en) Oxime derivatives, process for their preparation, pharmaceutical composition containing the same and medicinal use thereof
WO2011110876A8 (en) Novel salts for the manufacture of pharmaceutical compositions
MX2013000474A (en) Novel arylamide derivatives having antiandrogenic properties.
MX2010009922A (en) Pyridazinone glucokinase activators.
NZ594854A (en) Low-molecular polysulfated hyaluronic acid derivative and medicine containing same
WO2012018534A3 (en) Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases
WO2014078295A8 (en) Gemcitabine prodrugs and uses thereof
CA2920410C (en) Thienopiperidine derivative and use thereof
WO2011085643A8 (en) Fused pyridine derivatives
WO2012044531A8 (en) Novel piperazine analogs with substituted heteroaryl groups as broad-spectrum influenza antivirals
WO2011042860A3 (en) New derivatives of thieno[2,3-b]pyridine and 5,6,7,8-tetrahydrothieno[2,3-b]quinoline in particular useful in the treatment of malaria
FR2977252B1 (en) NOVEL ESTERS OF N-ACYLATED AMINO ACID DERIVATIVES AND ISOSORBID, PROCESS FOR THEIR PREPARATION, AND USE IN COSMETICS AND AS MEDICAMENT

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12844531

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12844531

Country of ref document: EP

Kind code of ref document: A2